Tags

Type your tag names separated by a space and hit enter

Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes.
Cardiovasc Diabetol. 2018 05 22; 17(1):73.CD

Abstract

BACKGROUND

Type 2 diabetes mellitus (T2DM) greatly increases the risks of cardiovascular disease and heart failure. In particular, left ventricular diastolic dysfunction that develops from the early stages of T2DM is an important factor in the onset and exacerbation of heart failure. The effect of sodium-glucose cotransporter 2 inhibitors on left ventricular diastolic function has not been elucidated. We have performed the first prospective study on the effects of canagliflozin on left ventricular diastolic function in T2DM.

METHODS

This study was performed to evaluate the effects of additional treatment with canagliflozin for 3 months on left ventricular diastolic function in patients with T2DM. A total of 38 patients with T2DM were consecutively recruited for this study. Left ventricular diastolic function was assessed by echocardiography. The primary study outcome was a change in the septal E/e' as a parameter of left ventricular diastolic function.

RESULTS

A total of 37 patients (25 males and 12 females) were included in the analysis. Mean age of participants was 64.2 ± 8.1 years (mean ± SD), mean duration of diabetes was 13.5 ± 8.1 years, and mean HbA1c was 7.9 ± 0.7%. Of the participants, 86.5% had hypertension, 100% had dyslipidemia, and 32.4% had cardiovascular disease. Canagliflozin significantly improved left ventricular diastolic function (septal E/e' ratio 13.7 ± 3.5-12.1 ± 2.8, p = 0.001). Furthermore, among the various parameters that changed through the administration of canagliflozin, only changes in hemoglobin significantly correlated with changes in the septal E/e' ratio (p = 0.002). In multiple regression analysis, changes in hemoglobin were also revealed to be an independent predictive factor for changes in the septal E/e' ratio.

CONCLUSIONS

This study showed for the first time that canagliflozin could improve left ventricular diastolic function within 3 months in patients with T2DM. The benefit was especially apparent in patients with substantially improved hemoglobin values. Trial registration UMIN Clinical Trials Registry UMIN000028141.

Authors+Show Affiliations

Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, 3-25-8, Nishi-Shinbashi, Minato-ku, Tokyo, 105-8461, Japan.Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, 3-25-8, Nishi-Shinbashi, Minato-ku, Tokyo, 105-8461, Japan. m-sakamoto@umin.ac.jp.Department of Cardiology, Jikei University School of Medicine, 3-25-8, Nishi-Shinbashi, Minato-ku, Tokyo, 105-8461, Japan.Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8654, Japan.Department of Pathology, Tsuruoka Kyoritsu Hospital, 9-34, Fumizonomachi, Tsuruoka-shi, Yamagata, 997-0816, Japan.Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, 3-25-8, Nishi-Shinbashi, Minato-ku, Tokyo, 105-8461, Japan.

Pub Type(s)

Journal Article
Observational Study

Language

eng

PubMed ID

29788955

Citation

Matsutani, Daisuke, et al. "Effect of Canagliflozin On Left Ventricular Diastolic Function in Patients With Type 2 Diabetes." Cardiovascular Diabetology, vol. 17, no. 1, 2018, p. 73.
Matsutani D, Sakamoto M, Kayama Y, et al. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovasc Diabetol. 2018;17(1):73.
Matsutani, D., Sakamoto, M., Kayama, Y., Takeda, N., Horiuchi, R., & Utsunomiya, K. (2018). Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovascular Diabetology, 17(1), 73. https://doi.org/10.1186/s12933-018-0717-9
Matsutani D, et al. Effect of Canagliflozin On Left Ventricular Diastolic Function in Patients With Type 2 Diabetes. Cardiovasc Diabetol. 2018 05 22;17(1):73. PubMed PMID: 29788955.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. AU - Matsutani,Daisuke, AU - Sakamoto,Masaya, AU - Kayama,Yosuke, AU - Takeda,Norihiko, AU - Horiuchi,Ryuzo, AU - Utsunomiya,Kazunori, Y1 - 2018/05/22/ PY - 2018/03/21/received PY - 2018/05/17/accepted PY - 2018/5/24/entrez PY - 2018/5/24/pubmed PY - 2019/1/29/medline KW - Autonomic function KW - Heart failure with preserved ejection fraction KW - Left ventricular diastolic function KW - Sodium-glucose cotransporter 2 inhibitors KW - Type 2 diabetes mellitus SP - 73 EP - 73 JF - Cardiovascular diabetology JO - Cardiovasc Diabetol VL - 17 IS - 1 N2 - BACKGROUND: Type 2 diabetes mellitus (T2DM) greatly increases the risks of cardiovascular disease and heart failure. In particular, left ventricular diastolic dysfunction that develops from the early stages of T2DM is an important factor in the onset and exacerbation of heart failure. The effect of sodium-glucose cotransporter 2 inhibitors on left ventricular diastolic function has not been elucidated. We have performed the first prospective study on the effects of canagliflozin on left ventricular diastolic function in T2DM. METHODS: This study was performed to evaluate the effects of additional treatment with canagliflozin for 3 months on left ventricular diastolic function in patients with T2DM. A total of 38 patients with T2DM were consecutively recruited for this study. Left ventricular diastolic function was assessed by echocardiography. The primary study outcome was a change in the septal E/e' as a parameter of left ventricular diastolic function. RESULTS: A total of 37 patients (25 males and 12 females) were included in the analysis. Mean age of participants was 64.2 ± 8.1 years (mean ± SD), mean duration of diabetes was 13.5 ± 8.1 years, and mean HbA1c was 7.9 ± 0.7%. Of the participants, 86.5% had hypertension, 100% had dyslipidemia, and 32.4% had cardiovascular disease. Canagliflozin significantly improved left ventricular diastolic function (septal E/e' ratio 13.7 ± 3.5-12.1 ± 2.8, p = 0.001). Furthermore, among the various parameters that changed through the administration of canagliflozin, only changes in hemoglobin significantly correlated with changes in the septal E/e' ratio (p = 0.002). In multiple regression analysis, changes in hemoglobin were also revealed to be an independent predictive factor for changes in the septal E/e' ratio. CONCLUSIONS: This study showed for the first time that canagliflozin could improve left ventricular diastolic function within 3 months in patients with T2DM. The benefit was especially apparent in patients with substantially improved hemoglobin values. Trial registration UMIN Clinical Trials Registry UMIN000028141. SN - 1475-2840 UR - https://www.unboundmedicine.com/medline/citation/29788955/Effect_of_canagliflozin_on_left_ventricular_diastolic_function_in_patients_with_type_2_diabetes_ L2 - https://cardiab.biomedcentral.com/articles/10.1186/s12933-018-0717-9 DB - PRIME DP - Unbound Medicine ER -